Peripheral Neuropathy: Diabetic, Guillain-Barré Syndrome, CIDP, and Electrodiagnostic Studies

Peripheral neuropathy refers to disorders affecting peripheral nerves outside the brain and spinal cord, encompassing motor, sensory, and autonomic nerve dysfunction. The three major categories discussed here represent distinct pathophysiologic mechanisms and clinical presentations.

Diabetic Peripheral Neuropathy (DPN)

[KEY_CONCEPT] Diabetic peripheral neuropathy is the most common cause of peripheral neuropathy worldwide, affecting up to 50% of patients with diabetes. The pathophysiology involves multiple mechanisms:

• Metabolic pathway dysfunction: Hyperglycemia leads to increased glucose flux through the polyol pathway, resulting in sorbitol accumulation and osmotic nerve damage
• Advanced glycation end products (AGEs): Protein glycation causes structural nerve damage
• Oxidative stress: Increased reactive oxygen species damage nerve fibers
• Microvascular ischemia: Diabetic microangiopathy reduces endoneurial blood flow

Guillain-Barré Syndrome (GBS)

[HIGH_YIELD] Guillain-Barré syndrome is an acute, immune-mediated demyelinating polyneuropathy with an incidence of 1-2 per 100,000. Pathophysiology includes:

• Molecular mimicry: Cross-reactivity between infectious agents (Campylobacter jejuni, CMV, EBV) and peripheral nerve antigens
• Complement activation: Antibody-mediated destruction of myelin sheaths
• Variants: AIDP (acute inflammatory demyelinating polyradiculoneuropathy) most common in Western countries; AMAN (acute motor axonal neuropathy) more common in Asia

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CIDP represents the chronic counterpart to GBS, with progressive or relapsing weakness developing over >8 weeks. The pathophysiology involves T-cell mediated immune responses against peripheral nerve myelin proteins, leading to chronic inflammation and demyelination.

[CLINICAL_PEARL] Unlike GBS, CIDP typically responds well to immunosuppressive therapy and has a more favorable long-term prognosis with treatment.

Diabetic Peripheral Neuropathy

[HIGH_YIELD] DPN presentation follows a characteristic pattern:

Early symptoms:

• Distal symmetric sensory loss in "stocking-glove" distribution
• Neuropathic pain: Burning, shooting, or electric shock-like sensations
• Paresthesias: Tingling, numbness, "pins and needles"
• Nocturnal symptom exacerbation

Physical examination findings:

• Reduced vibration sense (earliest sign) - test with 128 Hz tuning fork
• Diminished ankle reflexes (Achilles reflex lost first)
• Reduced pinprick and temperature sensation distally
• Muscle weakness in advanced cases (foot drop, intrinsic hand muscles)

Guillain-Barré Syndrome

[KEY_CONCEPT] GBS classic triad: Progressive symmetric weakness, areflexia, and minimal sensory involvement.

Clinical phases:

1. Progression phase (days to 4 weeks):

   • Ascending paralysis starting in legs
   • Facial weakness (50% of patients)
   • Respiratory muscle involvement (20-30% require mechanical ventilation)
   • Autonomic dysfunction: Cardiac arrhythmias, blood pressure fluctuations

2. Plateau phase (days to weeks)

3. Recovery phase (weeks to months)

Hughes Disability Scale assessment:

• Grade 0: Healthy
• Grade 1: Minor symptoms, able to run
• Grade 2: Able to walk 5m without assistance
• Grade 3: Able to walk 5m with assistance
• Grade 4: Chair/bed bound
• Grade 5: Requiring assisted ventilation
• Grade 6: Death

CIDP Clinical Features

CIDP presentation characteristics:

• Progressive or relapsing course over >8 weeks
• Symmetric proximal and distal weakness
• Sensory involvement more prominent than in GBS
• Cranial nerve involvement less common than GBS
• Treatment responsiveness to immunosuppression

[CLINICAL_PEARL] CIDP vs GBS timeline: If weakness progresses beyond 8 weeks or shows relapsing pattern, consider CIDP rather than GBS.

Electrodiagnostic Studies Overview

[HIGH_YIELD] Nerve conduction studies (NCS) and electromyography (EMG) are gold standard tests for peripheral neuropathy diagnosis and classification.

Nerve Conduction Study Parameters

Diabetic Neuropathy Diagnosis

Electrodiagnostic findings in DPN:

• Distal sensory involvement predominant
• Reduced SNAP amplitudes (axonal pattern)
• Mildly slowed conduction velocities
• Normal or mildly prolonged distal latencies

Supporting laboratory studies:

• Hemoglobin A1c: Assess glycemic control
• Fasting glucose/glucose tolerance test
• Vitamin B12, folate levels: Rule out deficiencies
• Thyroid function tests

GBS Electrodiagnostic Criteria

[KEY_CONCEPT] Electrodiagnostic criteria for AIDP (most common GBS variant):

Definite AIDP (≥3 of 4 criteria):

1. Motor conduction velocity <90% of normal in ≥2 nerves
2. Distal motor latency >110% of normal in ≥2 nerves
3. F-wave latency >120% of normal in ≥2 nerves
4. Conduction block or temporal dispersion in ≥1 nerve

CSF analysis in GBS:

• Elevated protein (>0.4 g/L)
• Normal or mildly elevated cell count (<10 cells/μL)
• Cytoalbuminous dissociation pattern

CIDP Diagnostic Criteria

Electrodiagnostic criteria for CIDP:

Definite CIDP requires ≥1 of: ├── Conduction block: >50% amplitude reduction ├── Temporal dispersion: Duration increase >30% ├── Distal motor latency >150% upper normal ├── Motor conduction velocity <70% lower normal └── F-wave latency >120% upper normal

Probable CIDP: 75% of above criteria met Possible CIDP: 50% of above criteria met

[CLINICAL_PEARL] Key differentiating feature: CIDP shows conduction block and temporal dispersion more prominently than GBS, indicating ongoing demyelination and remyelination.

Diabetic Peripheral Neuropathy Management

[HIGH_YIELD] DPN management focuses on glycemic control and symptomatic pain relief:

Glycemic Control

Target HbA1c <7% (individualized based on: ├── Patient age and life expectancy ├── Comorbidities ├── Hypoglycemia risk └── Patient preferences)

Intensive glucose control can prevent/slow progression but does not reverse established neuropathy

Neuropathic Pain Management Algorithm

First-line agents:

• Pregabalin: 75-150 mg BID, increase to 300-600 mg/day
• Gabapentin: 300 mg daily, titrate to 900-3600 mg/day in divided doses
• Duloxetine: 30 mg daily x1 week, then 60 mg daily

Second-line agents:

• Tricyclic antidepressants: Amitriptyline 25-75 mg at bedtime
• Topical agents: Capsaicin 0.075% cream, lidocaine patches

Third-line agents:

• Tramadol: 50-100 mg q6-8h
• Tapentadol: 50-100 mg BID

[CLINICAL_PEARL] Combination therapy often more effective than monotherapy for refractory neuropathic pain.

Guillain-Barré Syndrome Treatment

Acute Phase Management

Immunotherapy (start within 2-4 weeks of symptom onset):

Supportive care priorities:

• Respiratory monitoring: Serial FVC measurements, intubate if FVC <20 ml/kg
• Cardiac monitoring: Arrhythmia surveillance
• DVT prophylaxis: Sequential compression devices, anticoagulation if immobilized
• Pain management: Often severe, may require opioids
• Physical therapy: Prevent contractures, maintain mobility

[HIGH_YIELD] IVIG and plasmapheresis are equally effective; choice depends on availability and patient factors. Combining both treatments offers no additional benefit.

CIDP Treatment Algorithm

First-line treatment: ├── IVIG: 2 g/kg over 2-5 days, then maintenance ├── Corticosteroids: Prednisone 1 mg/kg/day └── Plasmapheresis: Alternative if IVIG/steroids unavailable

Second-line (steroid-sparing agents): ├── Methotrexate: 15-25 mg weekly ├── Azathioprine: 2-3 mg/kg/day ├── Mycophenolate: 1000-1500 mg BID └── Cyclophosphamide: Reserved for refractory cases

Maintenance strategy: ├── IVIG every 2-4 weeks (adjust based on response) ├── Prednisone taper to lowest effective dose └── Monitor for treatment response and side effects

[KEY_CONCEPT] CIDP treatment response timeline: Improvement typically seen within 2-3 months; if no response after 6 months of adequate treatment, reconsider diagnosis.

Diabetic Peripheral Neuropathy Complications

[HIGH_YIELD] DPN complications significantly impact morbidity and mortality:

Diabetic Foot Complications

Pathophysiology cascade:

• Sensory loss → Unrecognized trauma
• Motor weakness → Foot deformities, altered biomechanics
• Autonomic dysfunction → Decreased sweating, dry skin, fissures
• Vascular disease → Poor wound healing

Screening and prevention:

• Annual comprehensive foot exam: Monofilament testing, vibration sense, ankle reflexes
• Daily self-inspection patient education
• Proper footwear: Well-fitted, protective shoes
• Podiatric referral for high-risk patients

Charcot arthropathy:

• Acute phase: Warm, swollen, erythematous foot
• Chronic phase: Foot deformity, rocker-bottom appearance
• Management: Immobilization, non-weight bearing

Autonomic Neuropathy

Clinical manifestations:

• Cardiovascular: Resting tachycardia, orthostatic hypotension
• Gastrointestinal: Gastroparesis, diabetic diarrhea
• Genitourinary: Neurogenic bladder, erectile dysfunction
• Sudomotor: Anhidrosis, gustatory sweating

GBS Complications & Monitoring

Acute Complications

Respiratory failure (20-30% of patients):

• Monitoring parameters: FVC, NIF (negative inspiratory force), MEP (maximum expiratory pressure)
• Intubation criteria: FVC <20 ml/kg, NIF <-30 cmH2O, or clinical distress
• Weaning considerations: FVC >15-20 ml/kg, adequate cough

Autonomic dysfunction:

• Cardiac arrhythmias: Bradycardia, heart block, sudden cardiac death
• Blood pressure lability: Hypertension alternating with hypotension
• Monitoring: Continuous cardiac monitoring, frequent vital signs

Other complications:

• Venous thromboembolism: High risk due to immobilization
• Syndrome of inappropriate ADH (SIADH)
• Pain syndrome: Often severe, neuropathic character

Recovery and Prognosis

[CLINICAL_PEARL] GBS recovery predictors:

• Good prognosis: Age <40 years, absence of diarrheal illness, preserved CMAP amplitudes
• Poor prognosis: Age >60 years, rapid progression, severe axonal loss on EMG

Recovery timeline:

• 80-85% achieve full recovery within 6-12 months
• 10-15% have residual disability
• 5% mortality rate

CIDP Long-term Monitoring

Treatment Response Assessment

Outcome measures:

• INCAT disability score: Validated functional assessment
• Medical Research Council (MRC) sum score: Strength testing
• Grip strength: Quantitative strength measurement
• Serial NCS/EMG: Objective improvement documentation

Long-term Management Considerations

Treatment duration:

• Minimum 6-12 months before considering withdrawal
• Gradual tapering to identify minimum effective dose
• Long-term treatment may be necessary in 60-80% of patients

Monitoring for treatment complications:

• IVIG: Renal function, thrombosis risk, infections
• Corticosteroids: Osteoporosis, diabetes, hypertension, mood changes
• Immunosuppressants: CBC, liver function, infection risk

[KEY_CONCEPT] CIDP prognosis is generally favorable with treatment: 80-90% of patients respond to first-line therapy, and most maintain functional independence with appropriate management.